CNS Pharmaceuticals Reports Q1 2025 Financial Results with Increased Net Loss and Improved Cash Reserves

CNS Pharmaceuticals, Inc. reported its financial results for the first quarter of 2025, revealing a net loss of approximately $4.3 million, compared to a net loss of about $3.5 million for the same period in 2024. The increase in net loss is attributed to higher research and development expenses, which rose to approximately $3.2 million from $2.4 million year-over-year, primarily due to costs associated with data preparation and analysis for the topline data release of the Berubicin trial. General and administrative expenses slightly decreased to approximately $1.1 million from $1.1 million in the prior year, reflecting a mix of increased legal and professional fees offset by reductions in stock-based compensation and marketing expenses.

As of March 31, 2025, CNS Pharmaceuticals reported total assets of approximately $13.7 million, a significant increase from $8.7 million at the end of 2024. This growth was primarily driven by an increase in cash and cash equivalents, which rose to approximately $13 million from $6.5 million. The company’s working capital also improved to approximately $10.9 million, up from $6.2 million at the end of the previous fiscal year. The increase in cash was largely due to the sale of common stock under the AGP ATM Sales Agreement, which generated net proceeds of approximately $9 million during the quarter.

Operationally, CNS Pharmaceuticals has made strategic moves to enhance its product pipeline. The company entered into an Exclusive License Agreement with Cortice Biosciences, Inc. in July 2024, granting it rights to certain patents related to the compound TPI 287. This agreement is expected to bolster the company’s offerings in the oncology space, particularly for treating glioblastoma and other central nervous system tumors. The company is also in the process of evaluating potential paths forward for Berubicin, following the release of topline data from its clinical trial, which indicated comparable outcomes to the current standard of care, Lomustine.

Looking ahead, CNS Pharmaceuticals anticipates that its current cash reserves, bolstered by recent financing activities, will be sufficient to fund operations into the second half of 2026. The company plans to initiate a trial for TPI 287 and complete the final analysis of the Berubicin trial during this period. However, management has acknowledged the need for significant additional capital to support ongoing operations and future clinical trials, emphasizing that without successful fundraising, the company may need to implement cost-cutting measures or scale back its business plan. The company remains focused on securing further funding through equity offerings or other financing arrangements to ensure its continued operation and development of its drug candidates.